Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iobenguane (123I)
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Iobenguane (123I), marketed as MIBGen by ANSTO, is a radiopharmaceutical diagnostic agent used for the localization and imaging of neuroendocrine tumors, particularly those of adrenergic origin such as pheochromocytoma, neuroblastoma, and paraganglioma. It is a radioiodinated analog of guanethidine and acts as a structural analog of norepinephrine. The molecule is taken up by the norepinephrine transporter (NET) into presynaptic vesicles of sympathetic nerve endings and chromaffin cells. Once internalized, the Iodine-123 isotope emits gamma radiation, which is detected via Single Photon Emission Computed Tomography (SPECT) to visualize adrenergic tissues and tumors. It is administered intravenously and is primarily used in the assessment of catecholamine-secreting tumors and sympathetic innervation of the heart.
- Brand names
- MIBGen
- Other names
- iobenguane I 123[123I]meta-iodobenzylguanidineIobenguane-123I injectionIobenguane123I injectionIobenguane 123I injection123I MIBG
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on iobenguane (123I).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iobenguane (123I).